Hope for hepatitis delta patients: study seeks to end lifelong treatment
NCT ID NCT06603311
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predict if the virus will stay under control. The goal is to identify who can stop medication without the infection coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bulevirtide
What this could lead to
If successful, this could help doctors identify which hepatitis delta patients can safely stop bulevirtide without the virus returning, potentially reducing lifelong treatment.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply to everyone. The main risk is that stopping treatment could cause the virus to relapse, requiring restarting medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - University Hospital Berlin (Campus Virchow-Clinic); Department of Hepatology and Gastroenterology
Berlin, State of Berlin, 13353, Germany
-
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; Division of Gastroenterology and Hepatology
Milan, 20122, Italy
-
Hannover Medical School; Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology
Hanover, Lower Saxony, 30625, Germany
-
University Hospital Frankfurt; Medical Clinic 1
Frankfurt am Main, Hesse, 60590, Germany
-
University Hospital Heidelberg; Department of Internal Medicine IV: Gastroenterology, Hepatology, Infectious Diseases, Poisoning
Heidelberg, Baden-Wurttemberg, 69120, Germany